{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-253882","form_type":"8-K","ticker":"TPST","cik":"0001544227","company_name":"Tempest Therapeutics, Inc.","filed_at":"2023-10-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.470949+00:00","generated_at":"2026-06-10T01:39:16.610413+00:00","sec_items":["1.01","3.03","5.03","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Tempest TPST-1120 achieves 30% ORR vs 13.3% control in randomized HCC study; adopts poison pill","bullets":["Confirmed ORR 30% for TPST-1120 arm vs 13.3% control; duration of response not reached.","PFS HR 0.7 (median 7 mo vs 4.27 mo); OS HR 0.59 (median not reached vs 15.1 mo).","In beta-catenin mutation patients, cORR 43% and DCR 100%; in PD-L1 negative, cORR 27% vs 7% control.","Adopted limited duration rights plan; triggers at 10% (15% passive); expires Oct 2024 or 2026 if approved.","40% of TPST-1120 arm patients remain on treatment vs 16.7% control; safety comparable between arms."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-253882","json":"https://secwatch.observer/filing/0001193125-23-253882.json","markdown":"https://secwatch.observer/filing/0001193125-23-253882.md","text":"https://secwatch.observer/filing/0001193125-23-253882.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1544227/000119312523253882/0001193125-23-253882-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1544227/000119312523253882/d547808d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T01:39:16.610413+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a4e93ca0a2277129f2e82e106abcc952f71fe079","claim":"Tempest Therapeutics, Inc. entered into Rights Agreement with Computershare Trust Company, N.A. (effective 2023-10-10).","evidence_excerpt":"the Rights Agreement, dated as of October 10, 2023 (the “Rights Agreement”), by and between the Company and Computershare Trust Company, N.A., as Rights Agent","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1544227/000119312523253882/0001193125-23-253882-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Counterparty","value":"Computershare Trust Company, N.A."},{"label":"Effective","value":"2023-10-10"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}